COG Foundation News

Project:EveryChild: A game-changing resource in the fight against pediatric cancer

Project:EveryChild is a robust bank of blood and tissue samples from kids with cancer, and it's opening the door to groundbreaking advances. But what exactly is a biobank? And how do samples get there? Learn about the game-changing advances that Project:EveryChild is fueling.

Detailed tumor data is improving care and giving families and physicians hope

In 2022, the Children’s Oncology Group launched the Molecular Characterization Initiative. Diana Thomas, MD, PhD, who co-leads the project, explains molecular characterization testing, and how the research is already offering breakthroughs into how tumors are classified, leading to more individualized treatment.

The COG Foundation Annual Report - 2023

Message from The COG Foundation President, Douglas S. Hawkins, MD and Vice President, Lia Gore, MD.
Financial Summary - 2023
Research Expenditure Summary - 2023
The Year at a Glance

Defying Determinants of Health: One Scientist’s Mission to Improve Outcomes for Kids from Low-Income Families

How do social determinants of health (SDOH), things like poverty, and nutrition impact a child’s likelihood of their cancer relapsing? Read about how, Kira Bona, M.D., MPH, isn’t just answering the question, but developing new interventions to help increase survival rates for children from low-income families.

On the horizon — A future with minimal chemotherapy for babies with soft tissue tumors

First, Dr. Ted Laetsch proved that larotrectinib shrank tumors in kids who'd been treated with chemotherapy. His latest study showed larotrectinib could do the same — even without chemo.

How One COG Researcher is Working to Prevent Heart Failure in Childhood Cancer Survivors

It’s an alarming statistic: Pediatric cancer patients are five times more likely to develop heart failure compared to their peers. Thankfully, Dr. Saro Armenian's ground-breaking research is proving that risk can be significantly lowered.

COG research leads to game-changing improvements for pediatric Hodgkin lymphoma treatment

When scientists tested a new, more targeted treatment for pediatric Hodgkin lymphoma, they hoped it might work as well as the standard treatments. The results revealed something they never expected.

An immunotherapy with game-changing – life-saving – potential for patients with relapsed B-cell ALL

A new immunotherapy is providing another path to remission for relapsed B-cell ALL. Dr. Laura Hogan shares news of a long-awaited breakthrough for patients with the same pediatric cancer she had.

The Children’s Oncology Group Foundation newsletter is made possible by The Andrew McDonough B+ Foundation and Message Lab Media.

We hope that sharing stories about COG research breakthroughs, improved care, patient families and generous donors will strengthen and inspire
the pediatric cancer community.